Ipriflavone

Ipriflavone is a synthetic derivative of the isoflavone class, structurally related to compounds found in soy. It was developed as a bone density conservation agent and has been used primarily for the prevention and treatment of osteoporosis, especially in postmenopausal women. Ipriflavone works by inhibiting osteoclastic bone resorption—primarily through direct inhibition of osteoclast activity and modulation of intracellular free calcium—and may also affect preosteoclast recruitment or differentiation, possibly via effects on osteoblast response to parathyroid hormone. Unlike some other agents for osteoporosis, it does not possess estrogenic activity itself but can enhance the effects of estrogen when used in combination therapy. Ipriflavone has also been investigated for use in Paget disease, hyperparathyroidism-related bone loss, renal osteodystrophy, and other conditions involving pathological bone loss[1][2][3][5][6][8].

Other names

ipriflavona7-Isopropoxy-Isoflavone